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~acc~aromyce~ cerevisiae strains were transformed with plasmids coding for modified mating factor 011 lead- 
er sequences followed by glucagon. Glu~agon-containing peptides which were secreted into the fermentation 
broth were isolated and their amino acid sequences determined. The yeast strain transformed with the se- 
quence coding for the complete mating factor al leader sequence preceding the glucagon gene (MT556) se- 
creted glucagon plus glucagon extended at its N-terminal by parts of the leader sequence. The yeast strain 
transformed with the sequence coding for a truncated mating factor ~1~ leader sequence before the glucagon 
gene (MT615) secreted glucagon. These observations uggest hat S. cerevisiae is a suitable vehicle for the 
efficient expression of plasmids coding for polypeptides imilar to glucagon (e.g. VIP, secretin, GIP). 
Recombinant glucagon secretion; (Yeast) 
1. INTRODUCTION 
The pancreatic hormone glucagon is synthetized 
by the a-cells of the islets of Langerhans. In, for 
example, the rat the peptide is derived from a 180 
residue precursor molecule, preproglucagon, con- 
sisting of a twenty amino acid residue leader pep- 
tide and a 160 residue proglucagon fl]. In the 
pancreas, peptides formed from proglucagon by 
cleavages at Lys-Arg sequences include pro- 
glucagon l-30 or GRPP [2] and proglucagon 
33-61 or glucagon. In the yeast, Saccharomyces 
cerevisiae, enzymes within the secretory compart- 
ments [3,4] process the primary yeast mating fac- 
tor cyi (MFcrl) gene product (prepeptide-Lys- 
Arg-(Glu-Ala)~-OF-Lys-Arg-(Glu-~a)~-OF-(Lys- 
Arg-Glu-Ala-Asp-Ala-Glu-AlatiF)z [S]) into the 
mature a-factor tridecapeptide [6]. 
Correspondence address: A.J. Moody, Novo Research 
Institute, Novo ABC, DK-2880 Bagsvaerd, Denmark 
~b~~ev~a~~o~s~ MeCN, acetonitriie; GIP, gastric in- 
hibitory peptide; VIP, vasoactive intestinal peptide; 
GLI, glucagon-like immunoreactivity 
A series of genes for dibasic insulin precursors 
which were fused to a modified MFal leader se- 
quence have recently been expressed in a yeast 
system [7]. The availability of this system led us to 
examine the expression of a synthetic glucagon 
gene fused to the MFal leader sequence. Two 
plasmids were constructed which contained a syn- 
thetic gene for glucagon placed after either the 
complete MFcY~ Ieader sequence [S] {pMT544) or 
the leader sequence from which the portion coding 
for the last four residues (C&r-Ala-Glu-Ala) had 
been deleted (pMT612). S. cerevisiae was 
transformed with these plasmids. The glucagon- 
related peptides ecreted by the transformants were 
isolated and sequenced. 
2. MATERIALS AND METHODS 
2.1. Gene synthesis 
Oligonucleotides were synthesized on an 
automatic DNA synthesizer (model 38OA, Applied 
Biosystems, Foster City, CA) using phospho- 
ramidite chemistry on a silica support [8] or by 
semiautomatic olumn synthesis using the phos- 
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photriester approach with di- and trinucleotide 
blocks and a polystyrene support [9]. 
A synthetic gene for glucagon was constructed 
from the oligonucleotides I-V indicated in fig. 1. A 
66-mer was obtained by ligation of I and II in the 
presence of III used as a ‘splint’. Similarly a 
73-mer was obtained by ligation of III, IV, and V 
using II as a splint. The 66-mer and the 73-mer, the 
3 ‘-ends of which are complementary over 39 
bases, were annealed and the 3 ’ -ends were filled in 
using Klenow polymerase and deoxyribonucleotide 
triphosphates resulting in a 100 base pair double- 
stranded DNA molecule (fig. 1). The k;pnI-Hind111 
fragment of the synthetic gene was used for the 
construction of the expression plasmid pMT544. 
2.2. Expression ~~asmids 
The plasmid pMT544 (fig.2) is a YEPl3-derived 
E. co&-S. cerevisiae shuttle plasmid where an ex- 
pression cassette has been inserted in the BamHI 
site. The expression cassette consists of a triose 
phosphate isomerase promotor fragment fused to 
the sequence ncoding the MFal leader peptide [7] 
and followed by a synthetic adaptor 
(AGCTCACTCTC~GGTAC/CTTGAGAGTG) 
joining the Hind111 at position 263 [5] of the MFal 
leader to the KprrI of the synthetic glucagon 4-29 
gene. The adaptor also encodes glucagon l-3. 
Transcription is terminated by means of the MFal 
terminator sequences: the Hind111 of the synthetic 
glucagon gene is joined to the Hind111 at position 
451 of the MFaI sequence (51 and the expression 
cassette is ended at a BamHI approx. 0.8 kb 
downstream. The sequences encoding amino acids 
Glu-Ala-Glu-Ala immediately preceding the first 
amino acid of glucagon were removed by site- 
directed deletion mutagenesis (see below) to give 
the plasmid pKFN6. The expression unit from 
pKFN6 was transferred as a BarnHI-SphI (partial) 
2.1 kb fragment to plasmid CPOT [7] to give the 
plasmid pMT612 (fig.2). 
The plasmid pMT544 was transformed into a S. 
cerevisiae (cu, leu2, pep4-3) selecting for leucine 
protophy to give the transformant strain MT556. 
The plasmid pMT612 was transformed into a 
triose phosphate isomerase mutant of S. cerevisiae 
(a/a, Atpi/Atpi, pep4-3/pep4-3) selecting for 
growth on glucose to give the transformant strain 
MT615. 
2.3. Site-directed deletion mutagenesis 
The plasmid pMT544 was linearized by cutting 
in the unique XbaI site in the glucagon gene and 
then treated with .!ZxoIII nuclease under conditions 
such that approx. 250 nucleotides were removed 
from each 3 ’ -end of the linearized plasmid [IO]. A 
kinased 26-mer mutagenic deletion primer d(CT- 
TTGGATAAAAGACACTCTCAAGGT) was an- 
nealed to the mutation site. A double-stranded 
circular DNA was made by filling in with Klenow 
polymerase and ligation with T4 ligase thereby 
destroying the original XbaI site in the glucagon 
gene. After transformation of E. coli (MT172), 
mutants were identified by colony hybridization 
with the 5 ’ -32P-labelled deletion mutagenesis 
primer. 
The destroyed %a1 site in the glucagon gene 
was then reconstructed by ligation of a 4.4 kb 
BamHI-XhoI and a 0.9 kb BarnHI-K@I fragment 
(containing the glucagon (4-29) gene) from 
pMT544 with a 6.6 kb XhoI-KpnI fragment from 
a plasmid with the 12 base pair deletion (see fig.2). 
The ligation mixture was used to transform E. 
co& (MT172) and plasmids isolated from the 
transformants were screened for the presence of a 
%a1 site. The deletion was confirmed in four in- 
dependent plasmids by DNA sequencing [ 111. One 
plasmid, pKFN6, was selected for further use. The 
yeast strains were grown on YPD medium [7]. 
BisSerGlnGlyThrPheThrSerAspTyrSerLysTyrLeuAsp- 
I II 
i 
ml1 
GAGCACT+~TCAGGGTACCTTCACTTCTGACTACTCTAAATACTTGGAC- 
CtCgtgagagtcccatggaagtgaagaCTGATGAGATTTATGAACCTG- 
I 
111 IV 
SerArgArgAlaGlnAspPheValGlnTrpLeuMetAsnThr 
i 
XbaI Hind111 
TCTAGRAGAGCCCAAGACttcgtccaatggttgatgaac~cctaagcttcgg 
AGATCTTCTCGGGTTCTGAAGCAGGTTACCAACTACTTGTGGATTCGAAGCC 
L I 
V 
Fig. 1. Synthetic gene coding for glucagon 1-29. Capital 
letters, chemical synthesis; small letters, enzymatic 
prolongation. 
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pMT644 
11.6 kb 
MFalT/jl Hind111 
pMT612 
13.0 kb 
Fig.2. Yeast expression plasmids for glucagon. 
2.4. Analysis of products 
Glucagon-like immunoreactivities were assayed 
by radioimmunoassays using anti-glucagon sera 
K6248 (K6248 GLI) and K5563 (K5563 GLI) which 
recognize the N-terminal portion and C-terminal 
portion of glucagon, respectively [ 121. Glucagon 
was identified and estimated by high pressure Ii- 
quid chromatography (HPLC) by analyzing a sam- 
ple with and without added glucagon. Peptides 
with significant GLI, or those which eluted on 
HPLC to the same position as glucagon, were 
isolated as described in section 3 and fully se- 
quenced on a gas phase sequencer (model 47OA, 
Applied Biosystems, Foster City, CA) as described 
[13]. 
3. RESULTS 
3.1. Expression of glucagon 1-29 in yeast strain 
MT556 
The su~rnatant from the fermentation of yeast 
strain MT556 contained 177 nM K6248 GLI. 
Ethanol (96%) was added to 800 mi of the super- 
natant to give a final concentration of 5% (v/v). 
The supernatant was concentrated on a Sep-Pak 
column (Waters). Two thirds of the Sep-Pak 
eluate, corresponding to 533 ml supernatant, was 
passed through an ~tiglucagon-Sepharose coiumn 
(monoclonal antibody NOVO Glu 00102). The 
bound peptides were eluted at low pH and frac- 
tionated by HPLC on a IO pm Waters PBondopak 
C-18 column (3.9 x 300 mm). The A and B buffers 
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were 0.1% tri~uoroacetic acid (TFA) in HtO and 
0.07% TFA in MeCN, respectively. The column 
was equilibrated with 25% B (flow: 1.5 mb’min) 
and the peptides were eluted with a linear gradient 
of MeCN (I%/min) and detected at 276 nm. 
The peak containing K6248 GLI eluted in the 
same area as glucagon l-29. This fraction was 
dried in vacua, and the amino acid sequences of 
the constituent peptides determined, The expres- 
sion products consisted of: Glu-AIa-GIu-AIa- 
Glucagon I-29; Glu-Ala-Glucagon l-29 and 
glucagon I-29 in approximately equimolar 
amounts. The isolation of peptides with GLI 
secreted by MT556 is summ~ized in table 1. 
3.2. Expression of glucagon l-29 in yeast strain 
MT615 
Analytical HPLC profiles of the supernatant 
Table 1 
Purification of GLI-peptides from yeast strain MT556 
supernatant 
Step Volume GLI Yield 
(ml) (antibody (vo) 
K-6248) 
(nmol) 
Supernatant 800 142 100 
Sep-Pak concentrate 2 111 78 
Antiglucagon column 0.2 29 20 
HPLC 2.0 11 8 
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from MT615 (upper panel) and the same sample 
after the addition of glucagon (lower panel) are 
shown in fig.3. A peptide peak (& 20.24 min) was 
increased by the addition of glucagon and it was 
assumed that the peak represented glucagon. In 
two successive batches of MT615 supernatant he 
glucagon was 250 and 960 nM, as estimated by 
A28Onm 
0.04 
0.02 
0 
A28Onm 
0.04 
0.02 
0 
Fig.3. The identification of glucagon by HPLC in the 
supernatant from yeast ransformant MT615. 25~1 of 
supernatant (upper panel) or 25 pl supernatant plus 3 pg 
glucagon (lower panel) were analyzed on a 4.6 x 250 mm 
column of Nucleosil5 Frn C-18 equilibrated at1 ml/mm 
with 25% (v/v) MeCN in 100 mM ammonium formate 
(pH 3.5). The column was efuted after 5 min with a 
gradient of MeCN in ammonium formate (25-40% 
FigA. The isolation of glucagon from the SP Sephadex 
eluate prepared from the supernatant of yeast 
transformant MT615. 18 ml of eluate were pumped at 
1 mI/min onto a 4.6 x 250 mm column of Nucleosil 
5 /rm C-18 previously equilibrated at1 ml/min with 25% 
(v/v) MeCN in 100 mM ammonium formate (pH 3.5). 
The column was washed with 25% (v/v) MeCN in 
ammonium formate for a further 20 min. The peptides 
were then eluted with a gradient of MeCN in ammonium 
formate (25-30070 during 5 min then isocratic for a 
further 40 min) starting at the ieft hand end of the UV 
trace. The effluent corresponding to the UV peak at RT 
during 35 min). 58.95 was collected. 
HPLC. The GLI contents were 1156 and 3708 nM 
measured with antiserum K6248, and 557 and 
2145 nM measured with antiserum K5563. 
Analytical HPLC of the MT615 supematant 
separated the GLI into three fractions: the first 
eluted at a low concentration of MeCN and con- 
tained essentially only K4268 GLI; the second 
eluted just in front of glucagon and contained ap- 
proximately equimolar amounts of K4268 and 
K5563 GLI’s; the third contained equimolar 
amounts of K4268 and K5563 GLI’s and co-eluted 
with glucagon. 
Glucagon was isolated from MT61 5 supernatant 
as follows. 2 g of dry SP Sephadex C-25 were add- 
ed to 200 ml supernatant (PH adjusted to 4.3) and 
the suspension stirred for 20 min at room 
temperature. The SP Sephadex was recovered on a 
filter, washed with 50 ml of 25 mM ammonium 
formate (pH 3.5), and the bound peptides eluted 
with 0.5 M ammonium formate (pH 8.4). 
Glucagon was isolated from this eluate by reverse- 
phase HPLC (fig.4). The peptide was fully se- 
quenced (average respective yield, 93.3%) and 
shown to be glucagon. The isolation is summarized 
in table 2. 
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Table 2 
Recovery of glucagon from yeast strain MT615 
supernatant 
Step Volume Glucagona Yield 
(m0 (nmol) (%o) 
Supernatant 200 
Eluate from 
SP-Sephadex 18 
HPLC 1 
a As determined by HPLC 
192 100 
117 61 
118 61 
4. DISCUSSION 
Expression and secretion of significant amounts 
of glucagon-containing peptides was obtained by 
transforming S. cerevisiae with plasmids coding 
for the sequences: (a) MFal leader-glucagon 
(pMT544); (b) MFirl leader (minus the sequence 
coding for the C-terminal tetrapeptide)-glucagon 
(pMT612). 
The pMT544 transformant MT556 secreted 
glucagon (33%) plus two peptides consisting of 
either Glu-Ala-Glu-Ala or Glu-Ala from the MFcvl 
leader sequence attached to the N-terminal residue 
of glucagon. In previous studies using the entire 
MFal leader sequence for the expression of insulin 
precursors [7] or of epidermal growth factor 1141 
much lower percentages of products correctly pro- 
cessed at the N-terminal were obtained. One 
reason for this discrepancy could be that the struc- 
ture of glucagon is such that the Glu-Ala-Glu-Ala 
sequence was more accessible to processing en- 
zymes than was the case in the expression of 
epidermal growth factor and insulin precursors. 
The pMT612 transform~t MT615 secreted 
glucagon as well as unidentified peptides which 
reacted only with K6248. These peptides could 
have been formed by limited cleavage of the 
glucagon sequence (perhaps at the Arg-Arg in 
glucagon 17- 18) so that sequences containing only 
the epitope glucagon 11-15 were produced as well 
as intact glucagon 1-29. From previous studies it 
is known that the Arg-Arg and Lys-Arg sequences 
of proinsulin are cleaved rather rapidly, whereas 
other dibasic sequences uch as Lys-Arg in the 
disulphide bridge linked insulin precursor B-chain- 
Lys-Arg-A-chain are not cleaved [7]. These results, 
together with the present findings, indicate that 
dibasic sequences are extensively cleaved by the 
yeast enzyme system only when flanked by 
hydrophilic spacer peptides. The reason for the 
yeast enzyme system not processing at the 
Arg-1’7-Arg-18 sequence of glucagon might be 
that this sequence is not flanked by hydrophilic 
spacer peptide sequences. 
It is concluded that S. cerevisiae transformed 
with a plasmid (pMT612) containing a synthetic 
glucagon gene produces and secretes significant 
amounts of glucagon. Plasmids similar to pMT612 
could prove a suitable means for expressing other 
peptides structurally related to glucagon (e.g. 
secretin, VIP and GIP) in yeast. 
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